Search clinical trials for: Gallium Ga 68 Gozetotide

Total 239 results

Thomas Hope
Gateway for Cancer Research; Prostate Cancer Foundation; Conquer Cancer Foundation

Active, not recruiting

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Mayo Clinic

Withdrawn

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Jonsson Comprehensive Cancer Center

Recruiting

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma

United States
Mayo Clinic

Recruiting

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

Advanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8

United States
Jonsson Comprehensive Cancer Center

Terminated

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Jonsson Comprehensive Cancer Center

Terminated

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Mayo Clinic

Completed

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Telix Pharmaceuticals (Innovations) Pty Limited
Grand Pharmaceutical (China) Co., Ltd.

Recruiting

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Prostate Cancer | Biochemical Recurrence of Malignant Neoplasm of Prostate | BCR Prostate Carcinoma

China
Jonsson Comprehensive Cancer Center

Completed

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
University of Washington

Recruiting

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8

United States
Andrei Iagaru

Completed

Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | PSA Progression

United States
Mayo Clinic
National Cancer Institute (NCI); United States Department of Defense

Recruiting

68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer

Hepatocellular Carcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Invasive Breast Lobular Carcinoma | Metastatic Breast Lobular Carcinoma

United States
Mayo Clinic

Completed

PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer

Hepatocellular Carcinoma

United States
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8

United States
Chang Gung Memorial Hospital

Completed

Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer

Latent Cancer Prostate

Taiwan
Advanced Imaging Projects, LLC
All India Institute of Medical Sciences, New Delhi; US Department of Veterans... and other collaborators

Not yet recruiting

Safety and Efficacy of Ga68 Αvβ3 IAC PET/CT for Diagnosis and Clinical Management in Angiogenic Breast Cancer Patients (Shiva)

Angiogenic Breast Cancer

South Africa, India
University of California, San Francisco

Completed

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence (PSMA BCR)

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Meningioma | Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Von Hippel-Lindau Syndrome | Metastatic Well Differentiated Neuroendocrine Neoplasm | Somatostatin Positive Neoplastic Cells Present

United States
AHS Cancer Control Alberta

Recruiting

A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Neuroendocrine Tumors

Canada
Thomas Hope

Completed

Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence

Prostate Cancer

United States
University of California, San Francisco

Completed

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients (PSMA PreRP)

Prostate Cancer

United States
Mayo Clinic

No longer available

Expanded Access [Ga-68] PSMA-11 PET Imaging

Prostate Cancer

United States
Nantes University Hospital

Completed

TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors (68-DOTANOC-GEP)

Patients With Gastroenteropancreatic Neuroendocrine Tumors

France
Rahul Aggarwal
United States Department of Defense

Completed

Gallium-68 Citrate PET Used in Prostate Cancer

Prostatic Neoplasms

United States
Chang Gung Memorial Hospital
National Science and Technology Council

Not yet recruiting

FAPI in Rectal Cancer TNT

Rectal Neoplasms Malignant

Taiwan
Jonsson Comprehensive Cancer Center
Society of Nuclear Medecine and Molecular Imaging

Recruiting

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Breast Carcinoma | Gastric Carcinoma | Head and Neck Carcinoma | Lung Carcinoma | Ovarian Carcinoma | Colon Carcinoma | Esophageal Carcinoma | Kidney Carcinoma | Pancreatic Carcinoma | Uterine Corpus Cancer | Solid Neoplasm

United States
Mayo Clinic

Recruiting

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
Timothy Hoffman
University of Missouri-Columbia; Harry S. Truman Memorial Veterans' Hospital; Telix Pharmaceuticals, Ltd

Terminated

Ga-68-PSMA-11 in Men With Prostate Cancer (Ga68-PSMA-11)

Prostate Cancer | Prostate Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

Biochemically Recurrent Prostate Carcinoma

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Prostate Carcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Chang Gung Memorial Hospital

Recruiting

68Ga-PSMA PET/CT for Ra223 Assessment

Metastatic Prostate Cancer

Taiwan
UNC Lineberger Comprehensive Cancer Center

Active, not recruiting

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

Prostate Cancer

United States
University of Texas Southwestern Medical Center
Telix International Pty Ltd; Once Upon a Time Foundation

Recruiting

PSMA PET Response Guided SabR in High Risk Pca

Prostate Adenocarcinoma

United States
National Cancer Centre, Singapore

Active, not recruiting

PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers

Salivary Gland Tumor | Rare Malignant Neoplasm

Singapore
Chang Gung Memorial Hospital

Completed

The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Metastatic Prostate Cancer

Taiwan
Jonsson Comprehensive Cancer Center

Completed

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than Fifty

United States
Jonsson Comprehensive Cancer Center

Completed

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer (MSG PSMA PET)

Prostate Carcinoma

United States
The Methodist Hospital Research Institute

Completed

68 Ga-PSMA for High Risk Prostate Cancer

Prostate Cancer | High Risk

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy (PSMA SRT)

Recurrent Prostate Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors

Neuroblastoma | Ganglioneuroblastoma | Ganglioneuroma

United States
UNC Lineberger Comprehensive Cancer Center

Withdrawn

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Prostate Cancer

United States
Michael Graham PhD, MD

Active, not recruiting

Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer

Prostatic Neoplasms | Prostatic Neoplasms, Castration-Resistant

United States
Thomas Hope

Completed

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

Prostate Cancer

United States
Washington University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group (GALMYDAR)

Coronary Artery Disease

United States
Jin-Sook Ryu

Active, not recruiting

Ga-68 PSMA-11 PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: Digital PET/CT Versus Analog PET/CT

Prostate Cancer

Korea, Republic of
Endocyte

Recruiting

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Australia, South Africa
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Recurrent Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

Search clinical trials for: Gallium Ga 68 Gozetotide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations